| REVIEW ARTICLE |
|
| Year : 2022 | Volume
: 1
| Issue : 4 | Page : 217-233 |
|
|
Nucleic acid vaccines: A rising antidote for the future
W Roseybala Devi, Supriya S Kammar, S Logesh, Gareth Lawrence Dsouza, Thotegowdanapalya C Mohan, Charukesi Rajulu
Department of Biotechnology and Bioinformatics, Faculty of Life Sciences, JSS Academy of Higher Education and Research, Mysore, Karnataka, India
Correspondence Address:
Charukesi Rajulu
Department of Biotechnology and Bioinformatics, Faculty of Life Sciences, JSS Academy of Higher Education and Research, Mysore, Karnataka
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/jpdtsm.jpdtsm_85_22
|
|
|
DNA vaccines, a type of nucleic acid vaccine, have emerged as one of the recent developments in immunology and recombinant DNA technology, offering great potential in terms of ease of manufacture, maintenance, and safety compared to conventional vaccines. Since their discovery, DNA vaccines have evolved immensely, resulting in the employment of new techniques such as gene guns, in vivo electroporation, and nanoparticle-based carriers to enhance the delivery of vaccines into the cells. Starting from the failures of the first-generation DNA vaccines to the near-success second-generation vaccines, several strategies including codon optimization, antigen design, and heterologous prime-boost have greatly helped in strengthening the vaccine's immunogenicity. The purpose of developing these third-generation vaccines is primarily to solve existing medical complications like cancer, along with therapeutic uses, to address health problems, and to aid the rapid eradication of sudden global outbreaks of infectious diseases including Ebola and COVID-19. In this review, we focus on the recent developments and strategies employed to improve the efficacy of DNA vaccines and discuss their mechanism of action, potential concerns, progress achieved, and a brief update on its clinical applications.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
